This is a preview of subscription content, log in via an institution to check access.
References
Lane NE, Thompson JM, Strewler GJ, et al. Intermittent treatment with human parathyroid hormone (hPTH[1–34]) increased trabecular bone volume but not connectivity in osteopenic rats. J Bone Miner Res 1995 Oct; 10: 1470–7
Boyce RW, Paddock CL, Franks AF, et al. Effects of intermittent hPTH(1–34) alone and in combination with 1,25(OH)(2)D-3 or risedronate on endosteal bone remodeling in canine cancellous and cortical bone. J Bone Miner Res 1996 May; 11: 600–13
Sone T, Fukunaga M, Ono S, et al. A small dose of human parathyroid hormone(1–34) increased bone mass in the lumbar vertebrae in patients with senile osteoporosis. Miner Electrolyte Metab 1995 Jan–Jun; 21: 232–5
LM Prescott. New hormonal approaches for osteoporosis on the horizon. Inpharma 1997 Oct 4; 1107: 7–8
Finkelstein JS, Klibanski A, Arnold AL, et al. Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1–34): a randomized controlled trial. JAMA 1998 Sep 23–30; 280: 1067–73
Rights and permissions
About this article
Cite this article
Teriparatide. Drugs R&D 1, 222–224 (1999). https://doi.org/10.2165/00126839-199901030-00008
Published:
Issue Date:
DOI: https://doi.org/10.2165/00126839-199901030-00008